Ophthalmology Biosimilars Market: Molecule Type, Disease Type, and Geography

download arrow download arrow Download Free Sample
settings arrow settings arrow email us

Ophthalmology Biosimilars Market Size, Share, Growth, Trends, and Global Industry Analysis: Molecule Type (Aflibercept, Bevacizumab, Ranibizumab, Adalimumab), Disease Type (Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion,  Others), and Region

checked icon arrow_drop_down
checked icon Single User License $4400 $3520
checked icon Multiple User License $6600 $5280
checked icon Corporate User License $8900 $7120

1. Executive Summary
2. Global Ophthalmology Biosimilars Market Introduction
2.1. Global Ophthalmology Biosimilars Market – Taxonomy
2.2. Global Ophthalmology Biosimilars Market –Definitions
2.2.1. Molecule Type
2.2.2. Disease Type
2.2.3. Region
3. Global Ophthalmology Biosimilars Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Ophthalmology Biosimilars Market Dynamic Factors - Impact Analysis
3.6. Impact of COVID 19 on The Market
3.7. Three Forecast Scenarios - Pessimistic, Conservative, and Opportunistic
3.8. Mapping Market Players’ Activities
3.9. Recent Key Developments
3.10. Financial Status of the Market Players
3.11. Recent Acquisitions, Collaborations, and Mergers
4. Global Ophthalmology Biosimilars Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028
4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, US$ Million)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Ophthalmology Biosimilars Market Forecast, By Molecule Type, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, US$ Million)
5.1. Aflibercept
5.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, US$ Million)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Bevacizumab
5.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, US$ Million)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Ranibizumab
5.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, US$ Million)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Adalimumab
5.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, US$ Million)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
6. Global Ophthalmology Biosimilars Market Forecast, By Disease Type, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, US$ Million)
6.1. Age-related Macular Degenration
6.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, US$ Million)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Diabetic Macular Edema
6.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, US$ Million)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Retinal Vein Occlusion
6.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, US$ Million)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Others
6.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, US$ Million)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
7. Global Ophthalmology Biosimilars Market Forecast, By Region, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, US$ Million)
7.1. North America
7.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, US$ Million)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, US$ Million)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, US$ Million)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, US$ Million)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, US$ Million)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Ophthalmology Biosimilars Market - Opportunity Analysis Index, By Molecule Type, Distribution Channel, End User, and Region, 2022 - 2028
8. North America Ophthalmology Biosimilars Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, US$ Million)
8.1. Molecule Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%)
8.1.1. Aflibercept
8.1.2. Bevacizumab
8.1.3. Ranibizumab
8.1.4. Adalimumab
8.2. Disease Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%)
8.2.1. Age-related Macular Degenration
8.2.2. Diabetic Macular Edema
8.2.3. Retinal Vein Occlusion
8.2.4. Others
8.3. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (US$ Million) Y-o-Y Growth (%) and Market Share (%)
8.3.1. U.S.
8.3.2. Canada
8.4. North America Ophthalmology Biosimilars Market - Opportunity Analysis Index, By Molecule Type, Disease Type and Country, 2022 - 2028
8.5. North America Ophthalmology Biosimilars Market Dynamics – Trends
9. Europe Ophthalmology Biosimilars Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, US$ Million)
9.1. Molecule Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%)
9.1.1. Aflibercept
9.1.2. Bevacizumab
9.1.3. Ranibizumab
9.1.4. Adalimumab
9.2. Disease Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Age-related Macular Degenration
9.2.2. Diabetic Macular Edema
9.2.3. Retinal Vein Occlusion
9.2.4. Others
9.3. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (US$ Million) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Europe Ophthalmology Biosimilars Market - Opportunity Analysis Index, By Molecule Type, Disease Type and Country, 2022 - 2028
9.5. Europe Ophthalmology Biosimilars Market Dynamics – Trends
10. Asia-Pacific Ophthalmology Biosimilars Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, US$ Million)
10.1. Molecule Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%)
10.1.1. Aflibercept
10.1.2. Bevacizumab
10.1.3. Ranibizumab
10.1.4. Adalimumab
10.2. Disease Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Age-related Macular Degenration
10.2.2. Diabetic Macular Edema
10.2.3. Retinal Vein Occlusion
10.2.4. Others
10.3. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (US$ Million) Y-o-Y Growth (%) and Market Share (%)
10.3.1. Japan
10.3.2. China
10.3.3. India
10.3.4. ASEAN
10.3.5. Rest of Asia-Pacific
10.4. Asia-Pacific Ophthalmology Biosimilars Market - Opportunity Analysis Index, By Molecule Type, Disease Type and Country, 2022 - 2028
10.5. Asia-Pacific Ophthalmology Biosimilars Market Dynamics – Trends
11. Latin America Ophthalmology Biosimilars Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, US$ Million)
11.1. Molecule Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%)
11.1.1. Aflibercept
11.1.2. Bevacizumab
11.1.3. Ranibizumab
11.1.4. Adalimumab
11.2. Disease Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Age-related Macular Degenration
11.2.2. Diabetic Macular Edema
11.2.3. Retinal Vein Occlusion
11.2.4. Others
11.3. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (US$ Million) Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Argentina
11.3.3. Rest of Latin America
11.4. Latin America Ophthalmology Biosimilars Market - Opportunity Analysis Index, By Molecule Type, Disease Type and Country, 2022 - 2028
11.5. Latin America Ophthalmology Biosimilars Market Dynamics – Trends
12. Middle East and Africa Ophthalmology Biosimilars Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, US$ Million)
12.1. Molecule Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%)
12.1.1. Aflibercept
12.1.2. Bevacizumab
12.1.3. Ranibizumab
12.1.4. Adalimumab
12.2. Disease Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Age-related Macular Degenration
12.2.2. Diabetic Macular Edema
12.2.3. Retinal Vein Occlusion
12.2.4. Others
12.3. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (US$ Million) Y-o-Y Growth (%) and Market Share (%)
12.3.1. Saudi Arabia
12.3.2. GCC Countries
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA Ophthalmology Biosimilars Market - Opportunity Analysis Index, By Molecule Type, Disease Type and Country, 2022 - 2028
12.5. MEA Ophthalmology Biosimilars Market Dynamics – Trends
13. Competition Landscape 
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Molecule Type Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Amgen
13.2.2. Boehringer Ingelheim
13.2.3. Samsung Bioepis
13.2.4. Hetero Drugs
13.2.5. Novartis AG
13.2.6. Intas Pharmaceuticals Ltd.
13.2.7. Xbrane Biopharma
13.2.8. Formycon AG
13.2.9. Zydus Cadila
13.2.10. Biocon
13.2.11. mAbxience
14. Research Methodology
15. Key Assumptions and Acronyms

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

Key Market Players

  • Amgen
  • Boehringer Ingelheim
  • Samsung Bioepis
  • Hetero Drugs
  • Novartis AG
  • Intas Pharmaceuticals Ltd.
  • Xbrane Biopharma
  • Formycon AG
  • Zydus Cadila
  • Biocon
  • mAbxiencee

Related Industry Reports

Chronic Refractory Gout Pharmaceuticals Market

Familial Mediterranean Fever Pharmaceuticals Market

Australia Point of Care Diagnostics Market

Aseptic Sampling Market